Idarubicin Hexal

Idarubicin, the active ingredient in Idarubicin Hexal, is an anthracycline presented as a sterile injectable solution for intravenous administration. It functions as a cytotoxic agent used primarily in the management of acute myeloid leukemia, targeting malignant myeloid cells in adult patients undergoing intensive chemotherapy protocols.

GNH USA supplies Idarubicin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑assured product availability for clinical oncology programs, including academic medical centers and transplant units globally.

Idarubicin is an anthracycline antineoplastic agent indicated for specific hematologic malignancies.

Acute Myeloid Leukemia (AML): Used as part of induction or consolidation chemotherapy to achieve complete remission. Relapsed or Refractory AML: Provides an alternative cytotoxic option when prior regimens have failed. High‑Risk AML in Combination Therapy: Integrated with other agents to improve response rates in patients with adverse prognostic features.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: Gastrointestinal upset occurring during or after infusion. - Alopecia: Temporary hair loss affecting scalp and body hair. - Myelosuppression: Decrease in blood cell counts leading to anemia, neutropenia or thrombocytopenia. - Fatigue: Generalized tiredness often related to cytopenias. - Mucositis: Inflammation of the oral and gastrointestinal mucosa. - Diarrhea: Loose stools during treatment cycles.

Serious or Rare Side Effects: - Cardiotoxicity: Irreversible damage to cardiac muscle that may lead to heart failure. - Severe neutropenia with febrile episodes: High risk of infection requiring urgent medical care. - Hemorrhage: Bleeding complications due to thrombocytopenia. - Secondary malignancies: Potential induction of new cancers after prolonged exposure. - Hepatic toxicity: Elevated liver enzymes or liver dysfunction.

When using Idarubicin, clinicians should observe several safety measures.

Cardiac monitoring: Baseline and periodic echocardiograms to detect early cardiotoxicity. Hematologic monitoring: Frequent complete blood counts to manage myelosuppression. Renal function assessment: Evaluate creatinine clearance before each dose. Pregnancy considerations: Avoid use in pregnant or nursing women unless benefits outweigh risks. Concomitant drug review: Assess for agents that may exacerbate toxicity, especially other cardiotoxic or myelosuppressive drugs. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Idarubicin can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent anthracyclines: Increases risk of cumulative cardiotoxicity. - High‑dose cyclophosphamide: Potentiates myelosuppression and organ toxicity. - Live vaccines: May cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): May raise idarubicin plasma levels. - Anticoagulants (e.g., warfarin): Heightened bleeding risk due to thrombocytopenia. - Nephrotoxic agents (e.g., aminoglycosides): Require renal function monitoring.